AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00801047
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-50 mic per 1-2 min via PCA
Trial: NCT04363450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
Trial: NCT03095066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsules
Trial: NCT03095066
Drug: AVP-786-42.63
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Trial: NCT01649375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00382811
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 8 hours daily in 28 day cycles
Trial: NCT01124604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
Trial: NCT03751514
Drug: Azithromycin 500 mg
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
Trial: NCT02584504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Trial: NCT02584504
Drug: Non-statin Lipid-Modifying Therapy
RxNorm normalized name: LIPID MODIFYING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
Trial: NCT03012113
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03667352
Drug: Intravenous Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
Trial: NCT02502266
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00539838
Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00539838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT02318290
Drug: Opiates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
Trial: NCT01975610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 28 days
Trial: NCT01399008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00373945
Drug: Observational Study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01885910
Drug: Doxycycline 100mg
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100mg by mouth once daily
Trial: NCT01885910
Drug: Aczone 5% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aczone 5% gel twice daily
Trial: NCT01660893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT03532464
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
Trial: NCT03532464
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
Trial: NCT03090100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
Trial: NCT00344383
Drug: Norgestimate/Ethinyl Estradiol tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965443
Drug: Placebo 1 10 mg + Placebo 2 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
Trial: NCT03506750
Drug: IVC
RxNorm normalized name: DEXTROMETHORPHAN HYDROBROMIDE 10 mg / ACETAMINOPHEN 325 mg / PHENYLEPHRINE HYDROCHLORIDE 5 mg ORAL CAPSULE, LIQUID FILLED [Activcin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
Trial: NCT01094496
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02357069
Drug: LBEC0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept
Trial: NCT01941082
Drug: RO6867461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple ascending dose by intravitreal injection
Trial: NCT00069992
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath 1H dosing as per institutional SOPs Day -5 to -2
Trial: NCT03166111
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Trial: NCT02753127
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02753127
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05040906
Drug: H02+CHOP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Trial: NCT05040906
Drug: Rituxan +CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Trial: NCT03694873
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
Trial: NCT00773240
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, 75,000 SQ-T, daily during the trial period
Trial: NCT00773240
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet, matching the active treatment, daily during the trial period
Trial: NCT00528723
Drug: BDP/salbutamol HFA pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
Trial: NCT00528723
Drug: BDP/salbutamol CFC pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
Trial: NCT02229942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
Trial: NCT02694146
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
Trial: NCT04338438
Drug: Apatinib Mesylate tablets combined with S-1 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Mesylate tablets combined with S-1 capsules, p.o.
Trial: NCT01549964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets
Trial: NCT01861496
Drug: LiPlaCis
RxNorm normalized name: Diplacus aurantiacus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiPlaCis IV every 3 weeks on day 1, day 8
Trial: NCT01498952
Drug: MEDI-573 (1 of 3 doses)
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
Trial: NCT00579826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
Trial: NCT02060032
Drug: 1.2% simvastatin local drug delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02060032
Drug: Placebo local drug delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00440310
Drug: FOLFOX4 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
Trial: NCT00440310
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
Trial: NCT01513681
Drug: Lamictal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamictal® 200 mg Tablets
Trial: NCT04566653
Drug: Calcium Polystyrene Sulphonate 15g/60 mL water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Trial: NCT01352637
Drug: Placebo + Prolonged Imaginal Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Trial: NCT01352637
Drug: Placebo (sugar pill) + Virtual Reality Exposure
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Trial: NCT00624676
Drug: Lipo Hydroxy Acid
RxNorm normalized name: alpha hydroxy acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day
Trial: NCT00258076
Drug: EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00718328
Drug: Simvastatin 80 mg
RxNorm normalized name: simvastatin 80 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
Trial: NCT00718328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
Trial: NCT03902080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00332709
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg every 6 months
Trial: NCT00254410
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
Trial: NCT01794091
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg daily for 6 months
Trial: NCT01794091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244256
Drug: Clotrimazole + Gentamicin + Beclomethasone
RxNorm normalized name: betamethasone / clotrimazole / gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Clotrimazole + Gentamicin + Beclomethasone
Trial: NCT01244256
Drug: Clotrimazole + Gentamicin
RxNorm normalized name: betamethasone / clotrimazole / gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Clotrimazole + Gentamicin
Trial: NCT00689247
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, single dose
Trial: NCT01137942
Drug: clarithromycin, metronidazole, proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: appropriate dose of antibiotics and proton pump inhibitor
Trial: NCT02661594
Drug: APD421 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of amisulpride
Trial: NCT02661594
Drug: APD421 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supra-therapeutic dose of amisulpride
Trial: NCT02661594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator to establish baseline for calculating change in QTcF
Trial: NCT02276612
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
Trial: NCT01398111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pMDI
Trial: NCT00005833
Drug: R115777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg P.O. BID.
Trial: NCT03425929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Trial: NCT01116258
Drug: AZD5847
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, 15 days
Trial: NCT01116258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension, 15 days
Trial: NCT01939587
Drug: PBF-680 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01939587
Drug: PBF-680 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01939587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00885599
Drug: Herbal API
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Trial: NCT00885599
Drug: Cepacol
RxNorm normalized name: Cepacol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Trial: NCT00885599
Drug: placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
Trial: NCT01228630
Drug: Cloratadd-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
Trial: NCT02696369
Drug: 2% lidocaine HCl with epinephrine 1:200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02696369
Drug: 2% lidocaine HCl with epinephrine 1:80,000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02241499
Drug: Oxaliplatin and fluorouracil.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
Trial: NCT02357147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression.
Trial: NCT01220258
Drug: Azithromycin ophthalmic solution, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Trial: NCT04268420
Drug: FMP013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Falciparum Malaria Protein-13
Trial: NCT00368264
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azathioprine (2 mg/kg) plus four placebo infusions
Trial: NCT00066066
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
Trial: NCT02245542
Drug: ALNA®OCAS®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155738
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04918563
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
Trial: NCT01851720
Drug: Low dose fentanyl PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01851720
Drug: Standard IV fentanyl bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03674060
Drug: SYO-1644
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet
Trial: NCT02620904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006294
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
Trial: NCT01437007
Drug: TKM-080301
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004888
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00705978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03616912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01213979
Drug: 500 mg iron isomaltoside 1000
RxNorm normalized name: ferric carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
Trial: NCT01213979
Drug: 1000 mg iron isomaltoside 1000
RxNorm normalized name: ferric carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
Trial: NCT00854945
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
Trial: NCT01687491
Drug: ENOXA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparine 100 UI/Kg subcutaneous injection
Trial: NCT01687491
Drug: LOVENOX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparine 100 UI/Kg subcutaneous injection
Trial: NCT02032147
Drug: NGF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be treated with NGF 18u per day im for 60 days
Trial: NCT00555984
Drug: Propofol + Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously during surgery for maintenance of General Anesthesia